$SHPH Cashflow Statement | Understand Stock

$SHPH

$5.21 +$0.17 (3.27%) Close

$SHPH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Change in fair value of derivative liability
Amortization of right-of-use asset
Depreciation and amortization
Change in fair value of derivative liabilities
Amortization of debt discount and finance fees
Gain on marketable securities
Change in fair value of marketable securities
Gain on settlement of debt
Accrued interest settled with common stock
Loss on settlement of convertible debt
Gain on settlement of accounts payable
Gain on forgiveness of Paycheck Protection Program note payable
Gain on interest relief on conversion of notes payable
Stock-based compensation
Expense for debt issuance costs due to fair value election on convertible notes
Expense for issuance costs due to liability classified warrants
Loss on issuance of convertible notes - fair value option
Impairment of right-of-use asset
Interest payments on convertible notes accounted for at fair value
Change in fair value of convertible notes
Changes in operating assets and liabilities:
Accrued interest income
Prepaid expenses
Accounts payable and accrued expenses
Accounts payable and accrued expenses - related parties
Accrued interest payable
Accrued interest payable - related parties
Other assets
Change in operating lease asset and liabilities

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in marketable securities
Proceeds from disposition of marketable securities
Purchase of equipment
Payments made for capitalized software
Investment in developed technology related to Molecule.ai Asset Acquisition
Net cash (used in) provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares and exercise of warrants
Proceeds from note payable-related party
Proceeds from notes payable
Repayment of note payable-related party
Proceeds from convertible notes payable
Proceeds from issuance of common stock, warrants and pre-funded warrants, net of placement agent fees of $504,770
Payment for convertible notes finance costs
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $322,501
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $170,000
Proceeds from Issuance of Warrants
Payment of other issuance costs for issuance of common stock and equity-classified warrants
Payment for issuance costs related to liability-classified warrants
Proceeds from exercise of pre-funded warrants
Payment for finance costs
Payment of convertible note payable
Net cash provided by (used in) financing activities

Net change in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash paid for:
Interest
Common stock issued for conversion of accrued interest

Supplemental non-cash financing activities:
Shares issued for conversion of accrued interest
Common stock issued for conversion of convertible debt
Conversion of convertible notes accounted for at at fair value
Issuance costs in accrued expenses
Asset acquisition costs in accounts payable and accrued expenses
Common stock issued for settlement of debt
Common stock issued for exercise of warrants with settlement of notes payable
Common stock issued for dividend payable
Warrants issued for financing fees, net of issuance fees of $0 and $8,727, respectively
Initial recognition of right of use asset and liability
Common stock issued for Molecule.ai Asset Acquisition
Consideration payable recognized in asset acquisition
Contingent consideration recognized in asset acquisition

Comments